Targeting factor Xa and thrombin: impact on coagulation and beyond

Thrombosis and Haemostasis
Charles T Esmon

Abstract

Great advances have been made in recent years in understanding the haemostatic system and the molecular and cellular basis of thrombus formation. Although directly targeting factor Xa or thrombin (factor IIa) for effective anticoagulation is now well established, evidence has emerged suggesting that factor Xa and thrombin are involved in other physiological and pathophysiological cellular processes, including inflammation. These non-haemostatic activities of factor Xa and thrombin are predominantly mediated via the activation of proteinase-activated receptors. Studies have indicated a potential role of coagulation proteins (including factor Xa and thrombin) in the progression of disease conditions such as atherothrombosis. Preclinical studies have provided evidence for the effects of direct factor Xa or direct thrombin inhibition beyond anticoagulation, including anti-inflammatory activities and atherosclerotic plaque stabilisation. In this article, the non-haemostatic activities of factor Xa and thrombin and the effects of direct inhibition of these coagulation factors on these activities are summarised. In addition, the potential roles of factor Xa and thrombin in atherosclerosis and atherothrombosis are explored and the card...Continue Reading

References

Mar 1, 1987·The Journal of Clinical Investigation·F B TaylorK E Blick
Sep 17, 1996·Proceedings of the National Academy of Sciences of the United States of America·D J Stearns-KurosawaC T Esmon
Jul 5, 2001·Proceedings of the National Academy of Sciences of the United States of America·M Riewald, W Ruf
Jan 14, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Kenneth G MannKathleen Brummel
Jan 23, 2004·The Journal of Biological Chemistry·Tadamichi ShimizuHiroshi Shimizu
Dec 20, 2005·Journal of Thrombosis and Haemostasis : JTH·C FeistritzerM Riewald
Sep 23, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Florian BeaErwin Blessing
Nov 18, 2006·Blood·Laurent O MosnierJohn H Griffin
Aug 30, 2008·The New England Journal of Medicine·Bruce Furie, Barbara C Furie
Sep 9, 2008·Trends in Molecular Medicine·Keren BorensztajnC Arnold Spek
Apr 18, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Sarah T B G LoubeleHugo ten Cate
May 14, 2009·Maturitas·Charles T Esmon
Aug 21, 2009·Journal of Veterinary Emergency and Critical Care·Louis G Licari, Jan P Kovacic
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Dec 8, 2009·The New England Journal of Medicine·Sam SchulmanUNKNOWN RE-COVER Study Group
Dec 10, 2009·British Journal of Haematology·Pranita P SarangiMinsoo Kim
Jan 30, 2010·Critical Care Medicine·Marcel Levi, Tom van der Poll
Aug 11, 2010·Circulation·Julian Ilcheff BorissoffHenri M H Spronk
Nov 5, 2010·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators
Dec 7, 2010·The New England Journal of Medicine·Rupert BauersachsSebastian Schellong
Jan 14, 2011·Annual Review of Medicine·Bengt I ErikssonJohn W Eikelboom
Jan 22, 2011·Expert Opinion on Therapeutic Targets·Keren Borensztajn, C Arnold Spek
May 6, 2011·The New England Journal of Medicine·Julian Ilcheff BorissoffHugo ten Cate
Jul 26, 2011·The New England Journal of Medicine·John H AlexanderUNKNOWN APPRAISE-2 Investigators
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Sep 24, 2011·Arteriosclerosis, Thrombosis, and Vascular Biology·Leila M SevignyAthan Kuliopulos
Nov 15, 2011·The New England Journal of Medicine·Jessica L MegaUNKNOWN ATLAS ACS 2–TIMI 51 Investigators
Nov 24, 2011·Proceedings of the National Academy of Sciences of the United States of America·Stefania VetranoSilvio Danese
Mar 28, 2012·The New England Journal of Medicine·Harry R BüllerAnnelise Segers

❮ Previous
Next ❯

Citations

Nov 13, 2015·Expert Opinion on Pharmacotherapy·Mikhail S Dzeshka, Gregory Y H Lip
Oct 25, 2014·Expert Opinion on Drug Safety·Mikhail S Dzeshka, Gregory Yh Lip
Sep 24, 2015·Journal of Chemical Information and Modeling·Virginie Y MartinyBogdan I Iorga
Mar 1, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Atsushi OkadaUNKNOWN NaDEF Investigators
Mar 8, 2016·European Journal of Pharmacology·Qian HongYue Gao
Oct 19, 2016·Scientific Reports·Fumihiro SanadaRyuichi Morishita
Feb 28, 2017·Nature Reviews. Nephrology·Kristina N EkdahlBo Nilsson
Dec 23, 2016·Biochemical and Biophysical Research Communications·Yuanjun ZhuYinye Wang
Mar 16, 2017·Toxicon : Official Journal of the International Society on Toxinology·Rupamoni Thakur, Ashis K Mukherjee
Apr 4, 2018·Expert Opinion on Pharmacotherapy·Udaya S TantryPaul A Gurbel
Oct 22, 2014·Integrative Biology : Quantitative Biosciences From Nano to Macro·Douglas B Kell, Etheresia Pretorius
Dec 2, 2017·Acta Ophthalmologica·Jeroen BastiaansWillem A Dik
Sep 30, 2016·Pharmacological Reviews·Rithwik RamachandranMorley D Hollenberg
Jan 19, 2016·Journal of the Saudi Heart Association·Abdulla ShehabAhmed Eltayeb Yousif Ahmed Eltayeb
Apr 3, 2020·Journal of Thrombosis and Haemostasis : JTH·Jecko Thachil
Jul 6, 2018·Nature Reviews. Cardiology·Davide CapodannoDominick J Angiolillo
Jan 13, 2017·Journal of Thrombosis and Haemostasis : JTH·C LinC A Spek
Jan 19, 2020·Nature Reviews. Cardiology·Davide CapodannoDominick J Angiolillo
Nov 19, 2019·Hematology·Delphine BorgelFrançois Saller
Jul 21, 2020·Research and Practice in Thrombosis and Haemostasis·Edward L G PryzdialMarc Horwitz
Apr 5, 2020·International Journal of Molecular Sciences·Valery GoldermanEfrat Shavit-Stein
Jun 20, 2020·Current Cardiology Reports·Juan Simon Rico-MesaRobert Chilton
Jul 24, 2020·Journal of Applied Physiology·Jacky LautridouFrançois Guerrero
Sep 11, 2020·Journal of Thrombosis and Thrombolysis·Charalampos KartsiosSusan Fair
Mar 12, 2017·Heart and Vessels·Hiromasa KatohIchiro Michishita

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.